Immune Oncology Systems (IOS) is advancing a novel intratumoral drug delivery platform designed to enhance local tumor control while stimulating systemic anti-cancer immune responses.
The new paradigm of intraoperative immune activation and tumor decapitation.
Learn More
Sustained drug action combined with systemic immunotherapy (Abscopal effect).
Learn MoreAdvancing a robust clinical development strategy
| Program | Indication | Stage |
|---|---|---|
| IOS-101 | Resectable Pancreatic Cancer | Pre-IND |
| IOS-102 | Metastatic Pancreatic Cancer | IND Planning |
| IOS-201 | Solid Tumor Expansion Program | Discovery |
| IOS-301 | Chemical Conization – Cervical Precancerous Lesions (HPV+) | Clinical Practice |
| IOS-302 | Chronic Hepatitis B Cirrhosis & HBV-Negative Conversion | Clinical Practice |
| IOS-401 | Bone Cancer Theranostic (Imaging + Therapy) | Discovery |
| IOS-402 | Triple-Function Drug (Imaging + Radiotherapy + Chemotherapy) | Patent Filed |
| IOS-403 | Intratumoral Lu-177 Radio-Immunotherapy | Discovery |
Series A Fundraising · $50M · 27 Years Clinical Validation · 100,000+ Patients · Multi-Billion Dol...
Read More →Major Breakthrough in Gynecological Oncology! Academician Baofa Yu Announces New Non-Invas...
Read More →On August 8-10, the 10th China Translational Medicine Conference and China Precision Medicine Confer...
Read More →Diagnosed with Stage 4 Prostate Cancer with bone metastases, Mark Harris found hope with our Immune Slow Release Therapy. Within months, his metastatic lesions disappeared. Years later, he trusted our platform again to treat his wife's lung cancer when conventional chemotherapy failed. A true testament to the power of precision intratumoral immunotherapy.
We are actively seeking strategic collaborations to accelerate our development programs.
